Annexure - I

CIN NO.: L74899DL1985PLC022468

BRAWN

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2018 Rs. In Lakhs

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		3 months ended 31.12.2018 Un- audited	3 months ended 30.09.2018 Un-audited	3 months ended 31.12.2017 Un- audited	9 months ended 31.12.2018 Un- audited	9 months ended 31.12.2017 Un- audited	Accounting Year ended 31.03.2018 Audited
1	**Revenue from operations**						
	Revenue from operations	2,123.36	1,495.91	1,677.33	4,975.45	3,931.18	5,578.37
	Other Income	0.16	7.83	22.85	14.10	56.83	8.97
	Total Revenue	2,123.52	1,503.73	1,700.18	4,989.56	3,988.01	5,587.34
2	**Expenses**						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	1,933.27	1,347.14	1,512.23	4,472.65	3,498.50	4882.19
c	Change in inventories of finished goods, work in progress and stock in trade	2.34	(7.75)	(13.20)	1.70	(5.78)	2.46
d	Employee Benefit expenses	104.73	54.98	99.86	217.42	207.88	298.19
e	Depreciation and amortisation expenses	0.81	0.81	0.80	2.41	2.38	3.16
f	Finance Cost	2.18	1.14	0.67	3.97	1.74	5.73
g	Other expenses	43.75	52.45	45.38	146.88	118.62	199.50
	Total Expenses	2,087.07	1,448.77	1,645.74	4,845.03	3,823.35	5,391.23
3	**Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)**	36.44	54.96	54.44	144.53	164.66	196.11
4	**Other Income**	-	-	-	-	-	-
5	**Profit from ordinary activities before exceptional items (3-4)**	36.44	54.96	54.44	144.53	164.66	196.11
6	**Exceptional Items**	-	-	-	-	-	-
7	**Profit from ordinary activities before tax (5-6)**	36.44	54.96	54.44	144.53	164.66	196.11
8	**Tax Expenses**	10.23	15.65	15.94	41.72	52.62	67.94
9	**Profit (Loss) for the period from continuing operations (7-8)**	26.21	39.31	38.50	102.81	112.04	128.17
10	**Profit/(loss) from discontinuing operations**	-	-	-	-	-	-
11	**Tax expense of discontinuing operations**	-	-	-	-	-	-
12	**Profit/(loss) from Discontinuing operations (after tax) (10-11)**	-	-	-	-	-	-
13	**Profit (Loss) for the period (9+12)**	26.21	39.31	38.50	102.81	112.04	128.17
14	**Other Comprehensive Income**	0.33	1.31	(3.85)	5.45	(3.65)	(2.74)
	Total Comprensive Income	26.54	40.62	34.65	108.26	108.39	125.43
15	Details of equity share capital						
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital						463.06
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share	0.88	1.35	1.15	3.61	3.61	4.18
ii	Diluted earnings per share	0.88	1.35	1.15	3.61	3.61	4.18

NOTES :-

1. Results for the quarter and nine months ended on 31st Decemnber, 2018 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 11th February, 2019.
2. Statutory auditors have carried out the limited review of the financial results for the quarter and nine months ended on 31-12-2018
3. The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
4. The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
5. The above Standalone Un- audited Financial Results for the quarter and nine months ended on 31.12.2018 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
6. Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

For Brawn Biotech Ltd.

Director

Brij Raj Gupta
Managing Director
DIN NO. 00974969
Date : 11-02-2019
Place: Delhi

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462, Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462 Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48

BRAWN

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2018

(Rs. In Lakhs)

Sr. No	Particulars	Standalone					
		Quarter Ended			Nine Months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Un- audited	Unaudited	Un- audited	Un- audited	Un- audited	Audited
1	Total income from opearion	2,123.36	1,495.91	1,677.33	4,975.45	3,931.18	5,578.37
2	Net Profit/(Loss) from ordinary activities after tax	26.21	39.31	38.50	102.81	112.04	128.17
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	26.21	39.31	38.50	102.81	112.04	128.17
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	26.54	40.62	34.65	108.26	108.39	125.43
5	Equity Share Capital	300.03	300.03	300.03	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previos year	-	-	-	-	-	463.06
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)						
	(a) Basic (Rs.)	0.88	1.35	1.15	3.61	3.61	4.18
	(b) Diluted (Rs.)	0.88	1.35	1.15	3.61	3.61	4.18
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)						
	(a) Basic (Rs.)	0.88	1.35	1.15	3.61	3.61	4.18
	(b) Diluted (Rs.)	0.88	1.35	1.15	3.61	3.61	4.18

Notes:

1- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exhanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).

2- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11-02-2019.

3- The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable. The Company has for the first time adopted IND-AS beginning 01st April 2017 with transition date of 01st April, 2016.

4- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.

5- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

Place: Delhi
Date: 11-02-2019

For Brawn Biotech Ltd.

For and on behalf of Board
For Brawn Biotech Limited

Director

Brij Raj Gupta
Managing Director
DIN NO. 00974969

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462, Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462 Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48

Annexure - II

RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly Standalone Financial Results of BRAWN BIOTECH LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of Unaudited Financial Results of **Brawn Biotech Limited** (the "Company") for the quarter ended 31st December 2018 and the year to date results for the period 1st April 2018 to 31st December 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 18764N

Rajeev Jain

Rajeev Jain
(Partner)
Membership No. 99767
UDIN-19099767AAAAAC4297
Place: Delhi
Date:11-02-2019

Head Office : A-36, 1st Floor, Guru Nanak Pura, Near Metro Pillar No. 57, Vikas Marg, Laxmi Nagar, Delhi-110092
Phone : 011-49027875, Mobile : 9312253876, **E-mail :** info@rajivudai.com, rajiv@rajivudai.com
Web. : www.rajivudai.com